ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Antibiotics

U.K. antibiotics firm Amprologix launches

by Marc S. Reisch
September 29, 2018 | APPEARED IN VOLUME 96, ISSUE 39

 

09639-buscon14-amprologix.jpg
Credit: Ingenza/Kieran Chambers Photography
Amprologix is working on a new class of antibiotics.

Amprologix, a British start-up firm developing antibiotics that are effective against drug-resistant infections, has launched from the University of Plymouth to commercialize a new antibiotic, epidermicin. The antibiotic was initially recovered from a skin bacterium, Staphylococcus epidermidis. Ingenza, an industrial bioprocess expert, is helping Amprologix scale up epidermicin production and is also taking a stake in the new firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment